Sepsis Diagnostics Market Size to Hit Around USD 3.41 Bn by 2033
The global sepsis diagnostics market size was exhibited at USD 1.55 billion in 2023 and is projected to hit around USD 3.41 billion by 2033, growing at a CAGR of 8.2% during the forecast period 2024 to 2033.
Download Free Sample Copy for Better Understanding@ https://www.novaoneadvisor.com/report/sample/1742
Sepsis Diagnostics Market Key Takeaways:
Factors such as the introduction of technologically advanced diagnostic and treatment solutions, high prevalence of sepsis, and increasing awareness are responsible for market growth over the forecast period. Sepsis is the leading cause of death in high-income countries, such as the U.S., with approximately 270,000 people dying from the condition annually, according to the Centers for Disease Control and Prevention (CDC).
It is also prevalent in low and middle-income countries, where it often is undiagnosed and untreated due to limited access to healthcare. In 2020, the Global Sepsis Alliance reported that it is responsible for an estimated 11 million deaths worldwide each year, which is more than the combined number of deaths from breast cancer, prostate cancer, and HIV/AIDS. The situation is particularly severe in low-income countries, where disease-related mortality is the highest. As such, there is an urgent need for improving awareness, prevention, and treatment, particularly in these regions.
Pneumonia is the leading cause of sepsis and septic shock, affecting individuals of all ages. While community-acquired pneumonia and hospital-acquired pneumonia differ in symptom duration, both can result in severe pneumonia and an increased risk of developing sepsis. Recent studies indicate that sepsis is a direct outcome of pneumonia, with more than half of patients having suffered from pneumonia. Pneumonia and sepsis cases have significantly increased globally as a result of the COVID-19 pandemic. A study published in The Lancet Respiratory Medicine in August 2021 indicates that the prevalence of sepsis and mortality linked to sepsis have considerably increased throughout the pandemic.
The COVID-19 pandemic has further highlighted the importance of early diagnosisand treatment, as it can lead to organ dysfunction and increasing risk of developing sepsis. While the pathogenesis of COVID-19 is not yet fully understood, research suggests that cytokine and chemokine levels in severe COVID-19 patients are similar to those found in patients, highlighting the need for improved diagnostic tools for sepsis. Some companies offering advanced diagnostics for the disease are T2 Biosystems, Becton, Dickinson and Company (BD), and F. Hoffmann-La Roche. These companies are actively involved in developing diagnostic tools to provide faster and more accurate diagnosis, improve patient outcomes, and reduce the global burden of disease.
Hospital-acquired infections continue to be a major contributor to the development of sepsis diagnostics, particularly among patients with chronic conditions, such as diabetes. CDC reports that approximately 1 in 31 hospital patients in the U.S. acquires hospital-acquired infection each year. These infections often result from invasive medical procedures, such as catheter insertions, and can lead to sepsis. Catheter-Associated Urinary Tract Infections (CAUTIs) and Surgical Site Infections (SSIs) are the most common types of hospital-acquired infections.
Sepsis Diagnostics Market By Market Dynamics
The market is driven by technological advancements, such as molecular diagnostic technologies, multiplex assays, and biomarkers. For example, Roche Diagnostics offers products, such as the Elecsys BRAHMS PCT assay, which measures the levels of PCT in the blood. Several emerging trends are likely to shape market in the future. These include developing POC diagnostic tools, integrating Al & machine learning algorithms into diagnostics, and using biomarkers for disease diagnosis.
Regulatory bodies are crucial in driving the market and setting standards and guidelines for product development and approval. Recent trends focus on streamlining approval processes, promoting innovative technologies, and evidence-based clinical practices. The FDA has approved T2Bacteria Panel, which detects the disease-causing bacteria directly from a patient's blood sample without waiting for cultures to grow. This trend is likely to drive market growth during the forecast period.
Sepsis Diagnostics Market By Product Insights
Based on product type, blood culture media dominated the market in 2023 with a revenue share of more than 38.9%, as blood culture is considered the most cost-effective and convenient testing mode. In April 2019, BD launched the BD BACTEC platelet quality control media, which can help identify and decrease the incidence in patients receiving platelet transfusion. It enables blood banks, microbiology laboratories, and transfusion services to detect contaminated platelet units. Introduction of such new media is expected to fuel the segment’s growth.
Sepsis Diagnostics Market By Technology Insights
The microbiology technology segment dominated the market in 2023 and held the largest share of more than 48.9% of the overall revenue. Microbial culture is the primary and gold standard method for detecting infectious disease-causing organisms in laboratory settings.In addition, new strategic initiatives by key players will further drive the segment growth in near future. For instance, in April 2019, BD launched BD BACTEC platelet quality control media, which enables users to identify and decrease the incidence in patients receiving platelet transfusion.
Sepsis Diagnostics Market By Pathogen Insights
Bacterial segment held the largest revenue share of 86.0% of the market in 2023. It is anticipated to lead over the forecast period due to the rise in cases of bacterial sepsis, higher occurrence of hospital-transmitted infections, and rising number of surgical procedures conducted. According to the study published by SAGE Journals in January 2019, bacterial segment is the most common type, with 62.2% of patients infected with gram-negative bacteria and 46.8% with gram-positive bacteria. In the bacterial segment, the gram-negative bacteria sub-segment is anticipated to dominate the market over the forecast period.
Sepsis Diagnostics Market By Method Insights
The conventional diagnostics segment held the largest revenue share of 57.6% of the market in 2023. The conventional method relies on the expertise of healthcare professionals to evaluate the patient's clinical presentation and interpret laboratory and imaging results. Early detection and prompt treatment are crucial to improve patient outcomes.
Sepsis Diagnostics Market By End-user Insights
The hospital and clinics segment held the largest revenue size of 79.5% of the market in 2023, owing to an increase in hospitalization. Several ongoing developments to advance diagnostic tests are anticipated to boost the segment. In January 2023, FDA authorized IntelliSep, a novel diagnostic test that can assist in identifying patients with sepsis before the potentially fatal condition becomes too difficult to treat. Early detection is crucial for proper results as sepsis is responsible for one in three hospital deaths.
Sepsis Diagnostics Market By Testing Type Insights
The laboratory testing type segment dominated the market in 2023 with a share of 82.6%. Advancements in laboratory testing have made it easier and faster to detect sepsis, leading to better outcomes for patients. These tests use biomarkers, such as procalcitonin or cytokines, to identify the presence of infection in the body. The tests are sensitive and can provide results within hours, allowing for earlier detection and treatment of sepsis. Thus, these factors would further contribute to the development of more effective and personalized approaches to diagnosis.
Sepsis Diagnostics Market By Regional Insights
North America dominated the market in 2023 and held the largest revenue share of more than 44.4%. High incidence of sepsis and infectious diseases is expected to fuel demand for novel diagnostic solutions. Several developments have been reported in the region, contributing to market growth. For instance, in January 2023, Cytovale announced receiving FDA authorization for its IntelliSep Sepsis Test for early detection of sepsis.
Sepsis Diagnostics Market Recent Developments
Some of the prominent players in the global sepsis diagnostics market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global sepsis diagnostics market
Product
Technology
Pathogen
Testing Type
Method
End-user
领英推荐
Regional
Quick Buy This Premium Report From Here: https://www.novaoneadvisor.com/report/checkout/1742 ?
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
You can place an order or ask any questions, please feel free to [email protected] | +1 9197 992 333
About US
Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.
Connect with Us
Address: Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
IND Address: 2nd Floor,Shreeleela Plaza, Baner Road, Pune, Maharashtra - 411045
Call: USA - + 1 804 441 9344| IND - + 91 87933 22019 | Europe: +44 2080772818
Reasons to Purchase this Report
Nova One Advisor Group Offer Other Reports:
Cell Therapy Market Size and Forecast:?The global?cell therapy market size was exhibited at USD 4.85 billion in 2023 and is projected to hit around USD 37.42 billion by 2033, growing at a CAGR of 22.67% during the forecast period 2024 to 2033.
Gene Therapy Market Size and Forecast?:?The global?gene therapy market size was exhibited at USD 8.75 billion in 2023 and is projected to hit around USD 52.40 billion by 2033, growing at a CAGR of 19.6% during the forecast period 2024 to 2033.
Cell And Gene Therapy Manufacturing Market Size and Forecast:?The global?cell and gene therapy manufacturing market size was estimated at USD 9.95 billion in 2023 and is projected to hit around USD 106.03 billion by 2033, growing at a CAGR of 26.7% during the forecast period from 2024 to 2033.
Cell and Gene Therapy Market?Size and Forecast:?The global?cell and gene therapy market size was estimated at USD 18.13 billion in 2023 and is projected to hit around USD 97.33 billion by 2033, growing at a CAGR of 18.3% during the forecast period from 2024 to 2033.
U.S. Cell Therapy Market Size and Forecast:?The?U.S. cell therapy market size was estimated at USD 2.88 billion in 2023 and is projected to hit around USD 19.67 billion by 2033, growing at a CAGR of 21.18% during the forecast period from 2024 to 2033.
U.S. Gene Therapy Market Size and Forecast:?The?U.S. gene therapy market size ?was estimated at USD 3.19 billion in 2023 and is projected to hit around USD 18.50 billion by 2033, growing at a CAGR of 19.22% during the forecast period from 2024 to 2033.
T-cell Therapy Market Size and Forecast:?The global?T-Cell therapy market size ?was exhibited at USD 3.85 billion in 2023 and is projected to hit around USD 79.62 billion by 2033, growing at a CAGR of 35.38% during the forecast period 2024 to 2033.
Cancer Immunotherapy Market?Size and Forecast:?The global?cancer immunotherapy market? size was valued at USD 126.19 billion in 2023 and is projected to surpass around USD 296.01 billion by 2033, registering a CAGR of 8.9% over the forecast period of 2024 to 2033.
Immunotherapy Drugs Market?:?The global?immunotherapy drugs market size was valued at USD 240.19 billion in 2023 and is projected to surpass around USD 1,300.38 billion by 2033, registering a CAGR of 18.4% over the forecast period of 2024 to 2033.
Clinical Trials Market Size and Forecast:?The?global clinical trials market size was estimated at USD 81.90 billion in 2023 and is projected to hit around USD 153.59 billion by 2033, growing at a CAGR of 6.49% during the forecast period from 2024 to 2033.
Biologics Market Size and Forecast: The?global biologics market size was estimated at USD 511.04 billion in 2023 and is projected to hit around USD 1,374.51 billion by 2033, growing at a CAGR of 10.4% during the forecast period from 2024 to 2033.
Biotechnology Market Size and Forecast:? The?global biotechnology market size was estimated at USD 1.54 Trillion in 2023 and is projected to hit around USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% during the forecast period from 2024 to 2033.
Oncology? Market Size and Forecast: The?global oncology market size was estimated at USD 222.36 billion in 2023 and is projected to hit around USD 521.60 billion by 2033, growing at a CAGR of 8.9% during the forecast period from 2024 to 2033.
Cell And Gene Therapy Clinical Trials?Market Size and Forecast: The global cell and gene therapy clinical trials market size reached USD 11.62 billion in 2023 and is projected to hit around USD 47.40 billion by 2033, expanding at a CAGR of 15.09% during the forecast period from 2024 to 2033.
U.S. Clinical Trials Market Size and Forecast:?The?U.S. clinical trials market size was valued at USD 25.81 billion in 2023 and is projected to surpass around USD 41.57 billion by 2033, registering a CAGR of 4.88% over the forecast period of 2024 to 2033.
Active Pharmaceutical Ingredient CDMO Market:?The global active pharmaceutical ingredient CDMO market size was valued at USD 119.80 billion in 2023 and is anticipated to reach around USD 249.22 billion by 2033, growing at a CAGR of 7.6% from 2024 to 2033.
U.S. Pharmaceutical Market?:?The U.S. pharmaceutical market size was valued at USD 602.19 billion in 2023 and is projected to surpass around USD 1,093.79 billion by 2033, registering a CAGR of 6.15% over the forecast period of 2024 to 2033.
Viral Vector And Plasmid DNA Manufacturing Market:?The global viral vector and plasmid DNA manufacturing market size ?was valued at USD 6.19 billion in 2023 and is anticipated to reach around USD 39.30 billion by 2033, growing at a CAGR of 20.3% from 2024 to 2033.
U.S. Viral Vector And Plasmid DNA Manufacturing Market ;?The U.S. viral vector and plasmid DNA manufacturing market size was valued at USD 2.45 billion in 2023 and is expected to be worth around USD 15.30 billion by 2033, with a registered CAGR of 20.1% during forecast period 2024 to 2033.
Compounding Pharmacies Market :?The global compounding pharmacies market size ?was valued at USD 16.19 billion in 2023 and is anticipated to reach around USD 30.97 billion by 2033, growing at a CAGR of 6.7% from 2024 to 2033.
U.S. Compounding Pharmacies Market?:?The U.S. compounding pharmacies market size ?is projected to be worth around USD 10.76 billion by 2033 from USD 6.31 billion in 2024, at a CAGR of 6.1% from 2024 to 2033.
Antibiotics Market: The?global antibiotics market size ?was valued at USD 51.19 billion in 2023 and is projected to surpass around USD 85.80 billion by 2033, registering a CAGR of 5.3% over the forecast period of 2024 to 2033.
Biologics Market :?The?global biologics market size was estimated at USD 511.04 billion in 2023 and is projected to hit around USD 1,374.51 billion by 2033, growing at a CAGR of 10.4% during the forecast period from 2024 to 2033.
Biotechnology Market:?The?global biotechnology market size was estimated at USD 1.54 Trillion in 2023 and is projected to hit around USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% during the forecast period from 2024 to 2033.
Next Generation Sequencing Market?:?The?global next generation sequencing market size was estimated at USD 9.19 billion in 2023 and is projected to hit around USD 66.04 billion by 2033, growing at a CAGR of 21.8% during the forecast period from 2024 to 2033.
Genome Editing Market ;?The?global genome editing market size ?was valued at USD 8.45 billion in 2023 and is anticipated to reach around USD 40.48 billion by 2033, growing at a CAGR of 16.96% from 2024 to 2033.
U.S. Genome Editing Market:?The?U.S. genome editing market size was estimated at USD 3.55 billion in 2023 and is projected to hit around USD 16.49 billion by 2033, growing at a CAGR of 16.6% during the forecast period from 2024 to 2033.
U.S. Gene Synthesis Market?:?The?U.S. Gene Synthesis market size was valued at USD 700.90 million in 2023 and is projected to surpass around USD 3,118.73 million by 2033, registering a CAGR of 16.1% over the forecast period of 2024 to 2033.
Biopharmaceutical Market :?The global?Biopharmaceutical market size accounted for USD 327.46 billion in 2022 and is estimated to achieve a market size of USD 1,101.77 billion by 2032 growing at a CAGR of 12.9% from 2023 to 2032.
Immunotherapy Drugs Market?:?The?global immunotherapy drugs market size was valued at USD 240.19 billion in 2023 and is projected to surpass around USD 1,300.38 billion by 2033, registering a CAGR of 18.4% over the forecast period of 2024 to 2033.
Cancer Immunotherapy Market:?The global cancer immunotherapy market size was valued at USD 126.19 billion in 2023 and is projected to surpass around USD 296.01 billion by 2033, registering a CAGR of 8.9% over the forecast period of 2024 to 2033.
U.S. Plasmid DNA Manufacturing Market?:?The U.S. plasmid DNA manufacturing market size ?was valued at USD 711.90 million in 2023 and is projected to surpass around USD 4,885.15 million by 2033, registering a CAGR of 21.24% over the forecast period of 2024 to 2033.
U.S. Precision Medicine Market?:?The?U.S. precision medicine market size was valued at USD 24.95 billion in 2023 and is projected to reach around USD 76.12 billion by 2033, registering a CAGR of 11.80% from 2024 to 2033.